05:07p | Bentley Systems, Incorporated Declares Second Quarter 2022 Dividend | BU |
05:07p | Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay's Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors | BU |
05:06p | BEYOND MEAT, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) | AQ |
05:06p | Silvercorp reports adjusted earnings of $52.4 million, $0.30 per share, and cash flow from operations of $107.4 million for fiscal 2022 | AQ |
05:06p | F&M BANK CORP : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
05:06p | PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | AQ |
05:06p | Fanhua Announces Distribution of CNFinance Shares | AQ |
05:06p | Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO) | AQ |
05:06p | Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | GL |
05:06p | Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting | BU |
05:06p | Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting | GL |
05:06p | Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors | BU |
05:06p | Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting | GL |
05:05p | Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | AQ |
05:05p | Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022 | BU |
05:05p | MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022 | BU |
05:04p | LUFF ENTERPRISES Announces First Quarter Financial Results and Provides Corporate Update | AQ |
05:04p | NN INC : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) | AQ |
05:04p | ORASURE TECHNOLOGIES INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) | AQ |
05:04p | CPI CARD GROUP INC. : Submission of Matters to a Vote of Security Holders (form 8-K) | AQ |
05:04p | PCB BANCORP : Submission of Matters to a Vote of Security Holders (form 8-K) | AQ |
05:04p | TARONIS FUELS, INC. : Regulation FD Disclosure (form 8-K) | AQ |
05:04p | INVESTCORP INDIA ACQUISITION CORP : Other Events (form 8-K) | AQ |
05:04p | Splunk Ranks First in both IT Markets and Security Markets in Gartner® Market Share Report | BU |
05:04p | Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting | BU |
05:04p | ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO | BU |
05:04p | Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022 | BU |
05:04p | Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) | BU |
05:04p | Prairie Provident Reports on AGM Voting Results | GL |
05:04p | Prairie Provident Reports on AGM Voting Results | GL |
05:04p | Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 | BU |
05:03p | Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting | BU |
05:03p | Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response | BU |
05:03p | DYCOM INDUSTRIES INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K) | AQ |
05:02p | New Pivotal Data Demonstrate Clinical Benefit of Genentech's Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma | BU |
05:02p | Volatus Aerospace Corp. Announces Record First Quarter Annual Sales | AQ |
05:02p | DIME COMMUNITY BANCSHARES, INC. /NY/ : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
05:02p | Electra Makes Steady Progress in Q1 2022 Towards Commissioning its Cobalt Refinery | AQ |
05:02p | PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022 | AQ |
05:02p | University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | GL |
05:02p | Just Energy Announces Stay Extension and Adjournment of Motions for Meetings Order and Authorization Order | GL |
05:02p | Galane Gold Ltd. Releases Financial and Operating Results for Q1 | GL |
05:02p | EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022 | GL |
05:02p | Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy | BU |
05:01p | CAVCO : Fiscal Q4 Earnings Snapshot | AQ |